vs
Side-by-side financial comparison of CytomX Therapeutics, Inc. (CTMX) and NewAmsterdam Pharma Co N.V. (NAMS). Click either name above to swap in a different company.
NewAmsterdam Pharma Co N.V. is the larger business by last-quarter revenue ($19.1M vs $18.7M, roughly 1.0× CytomX Therapeutics, Inc.). CytomX Therapeutics, Inc. runs the higher net margin — -0.8% vs -90.7%, a 89.9% gap on every dollar of revenue. On growth, NewAmsterdam Pharma Co N.V. posted the faster year-over-year revenue change (740.1% vs -25.7%). CytomX Therapeutics, Inc. produced more free cash flow last quarter ($-15.8M vs $-37.8M).
CytomX Therapeutics is a clinical-stage biotechnology company specializing in innovative cancer immunotherapies. It leverages its proprietary Probody technology platform to develop targeted therapies that activate exclusively in tumor microenvironments, minimizing off-target toxicities, with a pipeline covering multiple solid tumor indications and partnerships with leading global pharmaceutical firms.
Kite Pharma, Inc. is an American biotechnology company that develops cancer immunotherapy products with a primary focus on genetically engineered autologous CAR T cell therapy - a cell-based therapy which relies on chimeric antigen receptors and T cells. Founded in 2009, and based in Santa Monica, California, it was acquired by Gilead Sciences in 2017.
CTMX vs NAMS — Head-to-Head
Income Statement — Q2 FY2025 vs Q2 FY2025
| Metric | | |
|---|---|---|
| Revenue | $18.7M | $19.1M |
| Net Profit | $-154.0K | $-17.4M |
| Gross Margin | — | — |
| Operating Margin | -6.9% | -186.1% |
| Net Margin | -0.8% | -90.7% |
| Revenue YoY | -25.7% | 740.1% |
| Net Profit YoY | 97.6% | 55.5% |
| EPS (diluted) | — | $-0.15 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q2 25 | $18.7M | $19.1M | ||
| Q1 25 | $50.9M | — | ||
| Q4 24 | $38.1M | $12.8M | ||
| Q3 24 | $33.4M | $29.1M | ||
| Q2 24 | $25.1M | — | ||
| Q1 24 | $41.5M | — | ||
| Q4 23 | $26.6M | — | ||
| Q3 23 | $26.4M | — |
| Q2 25 | $-154.0K | $-17.4M | ||
| Q1 25 | $23.5M | — | ||
| Q4 24 | $18.9M | $-92.2M | ||
| Q3 24 | $5.7M | $-16.6M | ||
| Q2 24 | $-6.5M | — | ||
| Q1 24 | $13.8M | — | ||
| Q4 23 | $837.0K | — | ||
| Q3 23 | $3.0M | — |
| Q2 25 | -6.9% | -186.1% | ||
| Q1 25 | 44.4% | — | ||
| Q4 24 | 46.4% | -338.5% | ||
| Q3 24 | 12.3% | -85.9% | ||
| Q2 24 | -33.7% | — | ||
| Q1 24 | 28.1% | — | ||
| Q4 23 | -2.3% | — | ||
| Q3 23 | 11.8% | — |
| Q2 25 | -0.8% | -90.7% | ||
| Q1 25 | 46.2% | — | ||
| Q4 24 | 49.6% | -721.7% | ||
| Q3 24 | 17.2% | -57.2% | ||
| Q2 24 | -26.0% | — | ||
| Q1 24 | 33.3% | — | ||
| Q4 23 | 3.1% | — | ||
| Q3 23 | 11.3% | — |
| Q2 25 | — | $-0.15 | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $-0.91 | ||
| Q3 24 | — | $-0.18 | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q4 23 | — | — | ||
| Q3 23 | — | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $49.0M | $739.2M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $119.9M | $778.5M |
| Total Assets | $175.1M | $815.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q2 25 | $49.0M | $739.2M | ||
| Q1 25 | $47.6M | — | ||
| Q4 24 | $38.1M | $834.2M | ||
| Q3 24 | $40.6M | $422.7M | ||
| Q2 24 | $43.2M | — | ||
| Q1 24 | $36.2M | — | ||
| Q4 23 | $17.2M | — | ||
| Q3 23 | $26.0M | — |
| Q2 25 | $119.9M | $778.5M | ||
| Q1 25 | $25.0M | — | ||
| Q4 24 | $-456.0K | $757.5M | ||
| Q3 24 | $-23.5M | $378.9M | ||
| Q2 24 | $-31.2M | — | ||
| Q1 24 | $-31.7M | — | ||
| Q4 23 | $-47.4M | — | ||
| Q3 23 | $-51.2M | — |
| Q2 25 | $175.1M | $815.1M | ||
| Q1 25 | $98.5M | — | ||
| Q4 24 | $120.5M | $864.6M | ||
| Q3 24 | $139.0M | $439.2M | ||
| Q2 24 | $159.2M | — | ||
| Q1 24 | $184.7M | — | ||
| Q4 23 | $201.8M | — | ||
| Q3 23 | $221.2M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-15.8M | $-37.7M |
| Free Cash FlowOCF − Capex | $-15.8M | $-37.8M |
| FCF MarginFCF / Revenue | -84.6% | -197.2% |
| Capex IntensityCapex / Revenue | 0.1% | 0.5% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-77.7M | $-119.7M |
8-quarter trend — quarters aligned by calendar period.
| Q2 25 | $-15.8M | $-37.7M | ||
| Q1 25 | $-21.0M | — | ||
| Q4 24 | $-19.9M | $-37.5M | ||
| Q3 24 | $-20.7M | $-12.5M | ||
| Q2 24 | $-19.5M | — | ||
| Q1 24 | $-26.0M | — | ||
| Q4 23 | $-22.0M | — | ||
| Q3 23 | $-18.2M | — |
| Q2 25 | $-15.8M | $-37.8M | ||
| Q1 25 | $-21.2M | — | ||
| Q4 24 | $-20.0M | $-37.5M | ||
| Q3 24 | $-20.7M | $-12.6M | ||
| Q2 24 | $-19.6M | — | ||
| Q1 24 | $-26.2M | — | ||
| Q4 23 | $-22.2M | — | ||
| Q3 23 | $-18.3M | — |
| Q2 25 | -84.6% | -197.2% | ||
| Q1 25 | -41.6% | — | ||
| Q4 24 | -52.5% | -293.5% | ||
| Q3 24 | -62.1% | -43.2% | ||
| Q2 24 | -78.2% | — | ||
| Q1 24 | -63.1% | — | ||
| Q4 23 | -83.5% | — | ||
| Q3 23 | -69.2% | — |
| Q2 25 | 0.1% | 0.5% | ||
| Q1 25 | 0.2% | — | ||
| Q4 24 | 0.2% | 0.0% | ||
| Q3 24 | 0.1% | 0.3% | ||
| Q2 24 | 0.4% | — | ||
| Q1 24 | 0.3% | — | ||
| Q4 23 | 1.0% | — | ||
| Q3 23 | 0.0% | — |
| Q2 25 | — | — | ||
| Q1 25 | -0.89× | — | ||
| Q4 24 | -1.05× | — | ||
| Q3 24 | -3.61× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | -1.89× | — | ||
| Q4 23 | -26.24× | — | ||
| Q3 23 | -6.10× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CTMX
| Bristol Myers Squibb Company | $11.6M | 62% |
| Astellas Pharma Inc | $4.6M | 25% |
| Regeneron Pharmaceuticals Inc | $2.1M | 11% |
NAMS
Segment breakdown not available.
